Anosheh Afghahi (PubMed) is a medical oncologist who serves as Medical Director at Flatiron Health where she applies her clinical knowledge and research expertise to accelerate outcomes research with a focus on clinicogenomics and breast cancer. She maintains a clinical practice seeing patients with breast cancer and has published in breast oncology on topics including cancer genetics, novel therapies, and outcomes research.

Prior to joining Flatiron, Anosheh was an Assistant Professor at the University of Colorado School of Medicine in the Division of Medical Oncology, where she also served as the Medical Director of the Hereditary Cancer Program.

Anosheh received her BA with highest distinction from the University of California, Berkeley. She then received an MD and MPH from Harvard Medical School and Harvard School of Public Health. She completed her internal medicine residency and medical oncology fellowship at Stanford University.

Ivy Altomare is a medical oncologist and hematologist who serves as a medical director at Flatiron Health, where she focuses on conducting outcomes research.

Prior to joining Flatiron in 2021, Ivy was an associate professor at Duke University and the assistant medical director of the Duke Cancer Network, where she practiced community oncology and hematology in underserved rural communities in North Carolina. She is an award-winning educator and maintains an oncology practice at Durham Veteran’s Hospital. 

Ivy received her undergraduate degree from the University of Pennsylvania and an MD from Rutgers New Jersey Medical School. She completed her residency and oncology fellowship at the Icahn School of Medicine at Mount Sinai.

Emily Castellanos is a medical oncologist and hematologist who serves as medical director at Flatiron Health, where she leverages her clinical and research expertise to develop innovative approaches to real-world evidence generation and inform product strategy.  She has a special interest in integrated approaches to real-world data, such as clinico-genomics, clinico-claims, or imaging data, as well as novel approaches to real-world study design. 

Prior to coming to Flatiron, she served on the faculty in the division of hematology/oncology at Vanderbilt University Medical Center. Emily also maintains a clinical practice specializing in breast malignancies at Fox Chase Cancer Center.

Emily earned her bachelor of science with distinction in biological sciences from Stanford University. She then received her MD from Vanderbilt University Medical Center, where she remained for her clinical training. She completed her residency in internal medicine, and after serving as chief resident she remained at Vanderbilt for her hematology/oncology fellowship and earned her MPH with a focus on health policy.

Cheryl Cho-Phan is a Medical Oncologist and serves as a Medical Director at Flatiron Health, where she applies her clinical expertise and research background to accelerate learning through the generation of real-world evidence, particularly in the area of clinicogenomics to improve patient care and outcomes.

Prior to joining Flatiron, Cheryl worked at Syapse as Director of Medical Oncology. Before Syapse, Cheryl was a Clinical Assistant Professor in the Department of Medicine, Division of Oncology at Stanford University where she was a clinical trial investigator focused on the care of patients with gastrointestinal malignancies.

Cheryl received her bachelor’s in environmental studies from Brown University and an MD from Georgetown University. She completed her internal medicine residency at Oregon Health Sciences University, and medical oncology fellowship at Stanford University.

Aaron Cohen is a medical oncologist, clinical informatician, and health outcomes researcher who serves as medical director at Flatiron Health. Aaron serves as the clinical lead for the machine learning team and focuses on the use of natural language processing and machine learning to facilitate cancer research and care.

Aaron has a faculty appointment at the NYU School of Medicine in the Department of Medicine and maintains a clinical practice at Bellevue Hospital, with a focus on solid organ malignancies. Prior to Flatiron, Aaron attended the University of Pennsylvania, where he completed his undergraduate and medical school training, as well as his master of science in Clinical Epidemiology. He completed his residency in internal medicine and fellowship in hematology and oncology at the Hospital of the University of Pennsylvania, where he served as chief fellow. He is board certified in internal medicine, medical oncology, and clinical informatics.

James Hamrick leads a team of doctors, nurses, and informatics specialists who inform the development and applications of the Flatiron HC™ products and services relied upon by front-line clinicians in hundreds of cancer clinics across the United States. 

James also maintains a clinical practice part-time at Kaiser Permanente of Georgia in Atlanta, where he previously served as chief of medical oncology and hematology.

James joined Flatiron from Kaiser Permanente of Georgia in 2016 and previously practiced oncology and hematology at Georgia Cancer Specialists. He is on the board of the Georgia Center for Oncology Research and Education, and previously served on the Kaiser Permanente National Inter-Regional Cancer Leadership Council and the KP National Cancer Chiefs Council.

James received his MD and an MPH in epidemiology from the University of North Carolina at Chapel Hill. He completed his residency and hematology/oncology fellowship at the University of California San Francisco.

James is board-certified in internal medicine, medical oncology, and hematology.

Neal J. Meropol, MD is a medical oncologist, clinical investigator and outcomes researcher who serves as Vice President of Research Oncology, and Scientific and Clinical Lead for Clinical Research at Flatiron Health. In this role, he provides leadership in leveraging Flatiron’s technology platforms to close the gap between research and clinical care.

Dr. Meropol’s research contributions span drug development and health services research, including evaluation of new agents, predictors of response and outcome, development of tools to overcome barriers to clinical trial participation, and assessment of the economic impact of care. His current focus is developing technologic innovations to enable clinical research to take place wherever care is delivered.

He is currently the appointed chair of the NCI Director’s Clinical Trials and Translational Research Advisory Committee (CTAC), and previously served as Chair of the National Cancer Institute Gastrointestinal Cancer Steering Committee. Dr. Meropol completed a four-year term as an elected member of the American Society of Clinical Oncology (ASCO) Board of Directors, and currently serves on the ASCO Research Committee. He also served as a member of the National Academies of Science, Engineering and Medicine National Cancer Policy Forum. A committed educator, Dr. Meropol was faculty and chair of the AACR/ASCO Methods in Cancer Clinical Research Vail Workshop, and ASCO Leadership Development Program. He has authored more than 300 manuscripts, book chapters, and editorials related to cancer prevention, treatment, decision making and health economics.

Prior to joining Flatiron, he served as Professor and Chief of the Division of Hematology and Oncology at University Hospitals Cleveland Medical Center and Case Western Reserve University, and Associate Director for Clinical Research at the Case Comprehensive Cancer Center.

Dr. Meropol holds a bachelor’s degree from Princeton University in Philosophy, and MD from Vanderbilt University. He was a resident in Internal Medicine at Case Western Reserve University, and completed Hematology and Medical Oncology fellowships at the University of Pennsylvania. He spent a sabbatical at the Leonard Davis Institute of Health Economics at the Wharton School of the University of Pennsylvania.

Rebecca Miksad, MD, MPH, is a medical oncologist and health outcomes researcher who serves as senior medical director at Flatiron Health. Rebecca oversees research collaborations with investigators from Flatiron’s academic partners and other scientific endeavors at Flatiron. 

In her roles, Rebecca leads teams generating real-world evidence, developing methods for real-world data analyses and producing clinically relevant insights from real world data. Rebecca also maintains a clinical practice at Boston Medical Center in Gastrointestinal Cancer. A nationally recognized clinician and researcher, Rebecca regularly publishes in leading medical journals, serves on national committees and lectures internationally. Previously on faculty at Harvard Medical School, Rebecca’s academic research has focused on improving cancer treatment decision-making through better characterization of patient outcomes and increasing relevance of clinical trial endpoints.

Rebecca earned a BA cum laude in economics from Harvard University and an MD with honors in research from Cornell University. She was a resident in internal medicine at Cornell University/New York-Presbyterian Hospital, and completed hematology and medical oncology fellowships at Harvard Medical School/BIDMC. Rebecca earned a MMS from Harvard Medical School and an MPH in Clinical Effectiveness from the Harvard School of Public Health in clinical effectiveness (with an emphasis on decision science). She also completed a post-doctoral fellowship in the Dana-Farber/Harvard Cancer Center Program in Cancer Outcomes Research Training (PCORT).

May Pini is a medical oncologist and serves as a Senior Medical Director, and Head of Research Oncology RWE, at Flatiron Health. May leverages her experience as a clinician and researcher to accelerate learning through the generation of real-world evidence in order to improve patient care and outcomes.

Prior to joining Flatiron, May worked for Premier, Inc., where she served as principal data scientist within the Informatics and Technology Services division, and most recently principal and co-lead of the Clinical Transformation team within the Population Health Advisory Services group. Before Premier, May was an assistant professor and health services researcher in the departments of Clinical Cancer Prevention and Gastrointestinal Medical Oncology at MD Anderson Cancer Center.

May received her undergraduate degree in chemistry from Stanford University. She received her MD and MPH from Vanderbilt University School of Medicine, and completed residency at Vanderbilt University Medical Center. After residency, May served as a primary care physician and quality improvement fellow at the Veterans Health Administration Tennessee Valley Healthcare System, and completed hematology/oncology fellowship training at the University of Michigan.

Trevor Royce is a radiation oncologist, clinical informatician, and health outcomes/policy researcher who serves as medical director at Flatiron Health, where he focuses on clinical research and collaborations with academic partners that leverage real-world evidence to accelerate progress in cancer treatment and improve patient outcomes.

Trevor has a faculty appointment at the Wake Forest School of Medicine in the Department of Radiation Oncology and maintains a clinical practice at a Veterans Affairs Medical Center with a focus on genitourinary cancers. Prior to joining Flatiron, he held a clinic and tenure-track faculty position at the University of North Carolina at Chapel Hill School of Medicine. Trevor regularly publishes in leading medical journals, serves on editorial boards and national committees and lectures nationally.

Trevor received his undergraduate degree in biomedical engineering from the University of Virginia and an MD from the University of North Carolina. He completed a radiation oncology residency at the Harvard Radiation Oncology Program where he served as Chief Resident and earned an MPH from the Harvard School of Public Health.